Table 1 Experimental combinations and outcomes for HCFs and iPSC-cFbs.

From: Chronic activation of human cardiac fibroblasts in vitro attenuates the reversibility of the myofibroblast phenotype

Cell type

Substrates (E)

Drug treatments

Treatment duration

Outcome

HCF

3 GPa, 25 kPa, 2 kPa

10 ng/ml TGF-β, 30 nM SD208, 10 μM SB431542

2–4 days

Proliferation: CyQUANT; RT-PCR: α-SMA, collagen 1; IF: α-SMA; western blot: α-SMA, collagen 1

hiPSC-cFb

3 GPa

10 ng/ml TGF-β, 30 nM SD208, 10 µM SB431542

2–4 days

Proliferation: CyQUANT; RT-PCR: α-SMA, collagen 1, collagen 3; IF: α-SMA

  1. α-SMA alpha-smooth muscle actin, E elastic modulus, HCF human cardiac fibroblast, IF immunofluorescence, hiPSC-cFb human induced pluripotent stem cell-derived cardiac fibroblast, TGF-β transforming growth factor-beta, RT-PCR real-time reverse transcriptase polymerase chain reaction.
Back to article page